Clinical Trial

Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study

Study acronym: PATH-HHT ATLAS
Completed
View on ClinicalTrials.gov →
Summary
This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT. This study is a longitudinal assessment of safety and effectiveness of pomalidomide in HHT in clinical trial participants following completion of the double-blind, placebo-controlled study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-04; most recent amendment 2026-07-09.
Status change: Active, Not Recruiting → Completed 2026-07-09
Trial Details
NCT Number NCT07018401
Lead Sponsor Massachusetts General Hospital
Collaborators: The Cleveland Clinic, University of North Carolina, Chapel Hill, University of California, San Francisco, Mayo Clinic, University of Utah, University of California, San Diego, University of Florida, Medical College of Wisconsin, Johns Hopkins University, University of Pennsylvania
Conditions Hereditary Hemorrhagic Telangiectasia (HHT)
Enrollment 62 participants
Start Date 2024-05-01
Primary Completion 2025-04-08 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-10